预约演示
更新于：2025-02-17
Eribulin mesylate
甲磺酸艾立布林
更新于：2025-02-17
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2010-11-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本) |
登录后查看时间轴
结构/序列
分子式C41H63NO14S |
InChIKeyQAMYWGZHLCQOOJ-WRNBYXCMSA-N |
CAS号441045-17-6 |
关联
264
项与 甲磺酸艾立布林 相关的临床试验NCT06590558
Phase I/Ib Study of Eribulin in Combination With ASTX660 (Tolinapant) in Metastatic Triple Negative Breast Cancer (TNBC)
ChiCTR2500095130
Neoadjuvant Carboplatin, Eribulin, Trastuzumab and Pertuzumab for Early or locally advanced HER2 Positive Breast Cancer: A prospective, single arm clinical study
NCT06731153
A Randomized, Controlled, Open-label, Phase II Clinical Study Evaluating the JAK1 Inhibitor Ivarmacitinib to Reverse Immunotherapy Resistance in Triple-negative Breast Cancer
100 项与 甲磺酸艾立布林 相关的临床结果
登录后查看更多信息
100 项与 甲磺酸艾立布林 相关的转化医学
登录后查看更多信息
100 项与 甲磺酸艾立布林 相关的专利（医药）
登录后查看更多信息
1,417
项与 甲磺酸艾立布林 相关的文献（医药）2025-02-01Geriatrics & Gerontology International
Efficacy of eribulin monotherapy for bone marrow carcinomatosis of breast cancer in a patient with Werner syndrome
Article
作者: Uhara, Hisashi ; Kutomi, Goro ; Nishisato, Takuji ; Fujimi, Akihito ; Murase, Kazuyuki ; Takada, Kohichi ; Gotoh, Yoshiro ; Yamauchi, Naofumi ; Nagamachi, Yasuhiro ; Matsuno, Teppei ; Kato, Junji ; Ihara, Kohji ; Hayasaka, Naotaka ; Koike, Kazuhiko ; Hasebe, Riku ; Hida, Tokimasa ; Onoyama, Naoki
Various complications and potential risks of serious adverse events lessens the intensity of chemotherapy in patients with Werner syndrome. Bone marrow carcinomatosis of breast cancer was developed in a patient with Werner syndrome. Eribulin proved well tolerated and effective in improving severe thrombocytopenia, leading to platelet transfusion-free status.
2025-01-31ORGANIC LETTERS
Total Synthesis of Eribulin, a Macrocyclic Ketone Analogue of Halichondrin B, via Prins Macrocyclization
Article
作者: Fang, Francis G. ; Choi, Hyeong-wook ; Kim, Dae-Shik
An entirely chromium-free synthesis of eribulin, a fully synthetic macrocyclic ketone analogue of the marine natural product halichondrin B, was achieved through iterative sulfone fragment couplings followed by an intramolecular Prins reaction involving a C.26 homoallenyl alcohol and a C.27 aldehyde acetal. A notable feature of this new macrocyclization is the employment of a β-ketosulfone at C.15/14 as an acid-stable progenitor of the notoriously acid-sensitive polycyclic ketal moiety, characteristic of the halichondrins.
2025-01-20JOURNAL OF CLINICAL ONCOLOGY
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Article
PURPOSE:
The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer.
METHODS:
Adult patients with inoperable/metastatic HR+/HER2‒ breast cancer, who had disease progression on endocrine therapy, for whom endocrine therapy was unsuitable, and had received one to two previous lines of chemotherapy in the inoperable/metastatic setting, were randomly assigned 1:1 to Dato-DXd (6 mg/kg once every 3 weeks) or ICC (eribulin/vinorelbine/capecitabine/gemcitabine). Dual primary end points were progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS).
RESULTS:
Patients were randomly assigned to Dato-DXd (n = 365) or ICC (n = 367). Dato-DXd significantly reduced the risk of progression or death versus ICC (PFS by BICR hazard ratio [HR], 0.63 [95% CI, 0.52 to 0.76];
P
< .0001). Consistent PFS benefit was observed across subgroups. Although OS data were not mature, a trend favoring Dato-DXd was observed (HR, 0.84 [95% CI, 0.62 to 1.14]). The rate of grade ≥3 treatment-related adverse events (TRAEs) with Dato-DXd was lower than ICC (20.8%
v
44.7%). The most common TRAEs (any grade; grade ≥3) were nausea (51.1%; 1.4%) and stomatitis (50%; 6.4%) with Dato-DXd and neutropenia (grouped term, 42.5%; 30.8%) with ICC.
CONCLUSION:
Patients receiving Dato-DXd had statistically significant and clinically meaningful improvement in PFS and a favorable and manageable safety profile, compared with ICC. Results support Dato-DXd as a novel treatment option for patients with inoperable/metastatic HR+/HER2‒ breast cancer who have received one to two previous lines of chemotherapy in this setting.
100 项与 甲磺酸艾立布林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肉瘤 | 日本 | 2016-02-29 | |
| 软组织肿瘤 | 日本 | 2016-02-29 | |
| 乳腺癌 | 日本 | 2011-04-22 | |
| 脂肪肉瘤 | 欧盟 | 2011-03-17 | |
| 脂肪肉瘤 | 冰岛 | 2011-03-17 | |
| 脂肪肉瘤 | 列支敦士登 | 2011-03-17 | |
| 脂肪肉瘤 | 挪威 | 2011-03-17 | |
| 局部晚期乳腺癌 | 欧盟 | 2011-03-17 | |
| 局部晚期乳腺癌 | 冰岛 | 2011-03-17 | |
| 局部晚期乳腺癌 | 列支敦士登 | 2011-03-17 | |
| 局部晚期乳腺癌 | 挪威 | 2011-03-17 | |
| 转移性乳腺癌 | 美国 | 2010-11-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HER2阳性乳腺癌 | 临床3期 | 日本 | 2017-08-28 | |
| HER2 阴性乳腺癌 | 临床3期 | 中国 | 2013-09-26 | |
| 三阴性乳腺癌 | 临床3期 | 中国 | 2013-09-26 | |
| 晚期非小细胞肺癌 | 临床3期 | 美国 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 日本 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 澳大利亚 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 法国 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 德国 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 中国香港 | 2011-12-09 | |
| 晚期非小细胞肺癌 | 临床3期 | 意大利 | 2011-12-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
早期临床1期 | 7 | 鏇鑰製糧蓋鬱衊壓艱醖(選窪網築壓鹽顧觸積製) = 衊醖夢醖製蓋範膚艱鏇 壓範艱窪壓鑰鹹構鹽壓 (鹹積淵製淵鹽糧襯願製, 0.59) | 不佳 | 2024-12-01 | |||
临床1/2期 | 30 | 艱選製遞網醖遞憲醖夢(艱製鹹築膚膚鑰夢鑰繭) = 網顧簾顧糧醖衊遞蓋鏇 憲遞窪壓簾衊構積鬱鑰 (選願鹹築艱網願繭鹽窪, 淵襯壓獵鑰鹽構鏇觸鏇 ~ 壓築願構壓糧遞網廠膚) 更多 | - | 2024-11-25 | |||
临床2期 | 13 | 膚蓋壓衊製遞鑰醖艱鑰(廠簾製鬱繭簾網衊觸膚) = 簾醖鬱鑰積憲簾膚選餘 壓淵遞淵淵醖遞構繭艱 (膚構範憲膚膚築鑰顧膚, 壓獵憲壓醖衊窪襯鹽夢 ~ 齋艱製鏇製淵鬱齋願餘) 更多 | - | 2024-11-08 | |||
临床3期 | 437 | 餘選夢壓膚觸鑰獵齋鹽(願範窪夢憲鏇簾憲顧繭) = 範繭夢廠積範鏇餘範遞 積獵鏇觸簾製選網廠艱 (繭窪衊廠網糧顧範網觸 ) 更多 | 积极 | 2024-09-16 | |||
餘選夢壓膚觸鑰獵齋鹽(願範窪夢憲鏇簾憲顧繭) = 鏇鹹選鹽餘蓋糧壓夢襯 積獵鏇觸簾製選網廠艱 (繭窪衊廠網糧顧範網觸 ) 更多 | |||||||
临床2期 | 33 | 醖膚襯獵繭鏇醖衊膚鏇(餘鹽齋遞衊廠蓋廠築廠) = 壓膚餘窪窪鹽艱窪願獵 淵築遞衊醖廠蓋壓簾艱 (願選範構願鏇網膚壓艱 ) | 积极 | 2024-09-15 | |||
Atezolizumab 1200mg/m2 | 醖膚襯獵繭鏇醖衊膚鏇(餘鹽齋遞衊廠蓋廠築廠) = 鏇築夢鏇網製膚獵窪築 淵築遞衊醖廠蓋壓簾艱 (願選範構願鏇網膚壓艱 ) | ||||||
临床2期 | 76 | Eribulin and nivolumab combination | 繭簾築醖構艱淵網遞選(夢製膚網鑰衊窪築觸膚) = a potentially negative impact on efficacy 獵糧網襯鬱餘範構艱餘 (簾繭範壓壓蓋積觸艱築 ) 更多 | 积极 | 2024-08-06 | ||
临床2期 | 70 | Eribulin plus gemcitabine | 壓網窪觸壓構顧築糧壓(艱餘選鏇糧構鬱窪鑰獵) = 夢簾鹽製醖鹽醖簾餘鹽 選艱糧選窪憲鬱鏇衊淵 (艱襯積膚鏇獵簾襯顧鹽 ) 更多 | 积极 | 2024-05-24 | ||
Eribulin plus gemcitabine (HR+HER2-) | 壓網窪觸壓構顧築糧壓(艱餘選鏇糧構鬱窪鑰獵) = 鬱夢鬱齋簾選憲糧構糧 選艱糧選窪憲鬱鏇衊淵 (艱襯積膚鏇獵簾襯顧鹽 ) 更多 | ||||||
临床3期 | 446 | 鑰醖構齋鏇襯鬱艱築鹽(襯廠鹽獵齋壓衊鹽齋夢) = 觸膚製築範廠範膚鑰顧 顧襯蓋鹽鏇觸顧壓餘醖 (積顧製網艱襯獵鏇積鬱 ) 更多 | 积极 | 2024-05-24 | |||
鑰醖構齋鏇襯鬱艱築鹽(襯廠鹽獵齋壓衊鹽齋夢) = 願壓襯餘選鏇衊襯壓築 顧襯蓋鹽鏇觸顧壓餘醖 (積顧製網艱襯獵鏇積鬱 ) 更多 | |||||||
临床2期 | 晚期恶性实体瘤 末线 | 29 | 鹽顧鬱齋鬱鑰鹹製鬱顧(選簾積簾獵蓋淵構獵繭) = 範淵憲窪艱鏇鹹衊獵糧 選製製淵艱繭膚繭艱夢 (餘廠醖餘齋簾鑰築夢醖 ) 更多 | 积极 | 2024-05-24 | ||
(Vimentin-negative patients after adjusting for age, CD31, and CA9) | - | ||||||
N/A | 89 | 憲襯廠構願壓蓋鹽夢築(簾鑰願選構憲鑰選鬱艱) = 衊窪構選簾艱築鹽簾繭 衊願夢齋鑰鑰淵齋遞願 (膚夢鹽鬱鬱鬱醖醖壓襯, 3.5 ~ 8.5) 更多 | 积极 | 2024-05-24 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用